TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16083201
Drug: Treated traction
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treated traction with routine conservative treatment
Study: 7846219
Drug: Metoprolol (14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (14 mg)
Study: 2923591
Drug: Atropine sulfate
Normalized name: Atropine Sulfate
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine sulfate (2 mg)
Study: 30475960
Drug: Apple flavanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apple flavanol extract (70 mg monomeric flavanols, 65 mg PCs)
Study: 30475960
Drug: Double dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dose of apple flavanol extract (140 mg monomeric flavanols, 130 mg PCs)
Study: 30475960
Drug: Apple PC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apple PC extract (130 mg PCs, 6.5 mg monomeric flavanols)
Study: 10410825
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline infusion
Study: 29933272
Drug: Dexmedetomidine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine infusion
Study: 8836934
Drug: Levodopa (LD)
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levodopa (LD) and carbidopa (300 mg and 75 mg respectively) with entacapone (400 mg)
Study: 8836934
Drug: Levodopa (LD)
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levodopa (LD) and carbidopa (300 mg and 75 mg respectively) with placebo
Study: 29806132
Drug: Curcumin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin (500 mg capsules, total: 1,000 mg twice daily for 12 weeks)
Study: 26497665
Drug: Motivational enhancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational enhancement therapy plus cognitive behavioural therapy
Study: 22104388
Drug: Emergency medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emergency medicine (EM) physicians
Study: 22104388
Drug: Pediatric emergency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pediatric emergency medicine (PEM) physicians
Study: 22913889
Drug: Metformin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin plus colesevelam
Study: 21672339
Drug: Metformin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin plus placebo
Study: 30047216
Drug: Semaglutide 0.25
Normalized name: SEMAGLUTIDE 0.25MG/0.375ML INJ PEN 3ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semaglutide 0.25 mg
Study: 24441673
Drug: Topically applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topically applied tazarotene for chemotherapy of BCC lesions
Study: 12819076
Drug: Zinc sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulfate (45 mg elemental zinc thrice daily for 9 days starting 2 days before each vaccine dose)
Study: 1610710
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg fusidic acid, administered twice daily for 6 days
Study: 6092554
Drug: Alternating chemotherapy
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating chemotherapy (VAM)
Study: 6092554
Drug: Sequential chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential chemotherapy (POCC)
Study: 26843153
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation for 28 days during antimalarial treatment
Study: 26843153
Drug: No iron
Normalized name: No Iron Multivitamin with Minerals
Approvals — FDA: no, EMA: no, PMDA: no
Description: No iron supplementation during antimalarial treatment
Study: 9232361
Drug: 1.0 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 g/kg glucose
Study: 9232361
Drug: 0.5 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g/kg glucose
Study: 6311913
Drug: DPT +
Normalized name: Diphtheria, Pertussis, and Tetanus Vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPT + PRP vaccine
Study: 6311913
Drug: DPT vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPT vaccine
Study: 29726319
Drug: Outpatient chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient chemotherapy (group B: three treatments in an outpatient clinic followed by four at home)
Study: 26730818
Drug: TPV/r 500/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPV/r 500/100 mg
Study: 26730818
Drug: TPV/r 500/200
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPV/r 500/200 mg
Study: 24138537
Drug: LPV/r 400/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPV/r 400/100 mg
Study: 1993488
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg omeprazole once daily
Study: 8618582
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg famotidine twice daily
Study: 12719045
Drug: rocuronium (0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: rocuronium (0.9 mg kg(‐1))
Study: 12719045
Drug: mivacurium (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: mivacurium (0.25 mg kg(‐1))
Study: 11303324
Drug: Elevated homocysteine
Normalized name: mecysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elevated homocysteine level defined as > or = 12.83 mumol/L
Study: 11303324
Drug: 5 mumol/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mumol/L increment in homocysteine level
Study: 1290619
Drug: Losartan (DuP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (DuP 753, MK‐954) at doses of 5, 10, 20, 40, 80, and 120 mg
Study: 6365501
Drug: Blood-glucose self-testing
Normalized name: BLOOD/GLUCOSE/LEUKOCYTES/PROTEIN TEST
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood-glucose self-testing (5 tests daily)
Study: 23958540
Drug: Linaclotide 290
Normalized name: LINACLOTIDE 290MCG CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linaclotide 290 μg once daily for 26 weeks
Study: 21081243
Drug: Metreleptin (0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metreleptin (0.04 mg/kg subcutaneously once daily; n = 5)
Study: 10834715
Drug: 0.2 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg/day of rHGH
Study: 8864715
Drug: Pentoxifylline 400
Normalized name: pentoxifylline 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline 400 mg t.i.d. for 9 months
Study: 1741200
Drug: Continuous amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous amoxicillin (twice a day every day for up to 4 months)
Study: 1741200
Drug: Intermittent amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent amoxicillin (twice a day only when respiratory symptoms developed for up to 4 months)
Study: 1741200
Drug: Continuous amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous amoxicillin
Study: 27905821
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of booster hepatitis B vaccination (0-1-6 month, 20 µg)
Study: 22027731
Drug: Drug-eluting balloon
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-eluting balloon (DEB)
Study: 16854683
Drug: Mifepristone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone (10 mg)
Study: 15572495
Drug: Levonorgestrel (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel (2 doses of 750 microg given 12 hours apart)
Study: 31763316
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical treatment (Group B)
Study: 29348382
Drug: Ophiocephalus striatus
Normalized name: Labrus striatus flesh
DrugBank: Black sea bass (DB15547)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophiocephalus striatus extract (10 g per day for 14 days)
Study: 17697449
Drug: Etoricoxib (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib (90 mg daily)
Study: 12009282
Drug: SPf66/QS-21 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPf66/QS-21 vaccine
Study: 12009282
Drug: SPf66/alum vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPf66/alum vaccine
Study: 7301160
Drug: Preoperative skin
Normalized name: POVIDONE-IODINE 75 mg in 1 mL TOPICAL SOLUTION [Antiseptic Patient Preoperative Skin Preparation and Surgical Hand Scrub]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative skin disinfection with povidone-iodine 10% (Betadine) and application of 10% povidone-iodine solution before skin closure.
Study: 23999674
Drug: High AA
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High AA group: 3 g/kg/d of parenteral amino acids, increasing by 1 g/kg daily until a maximum of 4 g/kg/d
Study: 19016815
Drug: Oral antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antibiotics (ciprofloxacin and metronidazole)
Study: 12795852
Drug: Paclitaxel liposome
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel liposome at 135 mg/m² each session, combined with ADM or DDP for two cycles (3 weeks per cycle)
Study: 11017151
Drug: Altered peptide
Normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Altered peptide ligand of myelin basic protein (5 mg)
Study: 2873863
Drug: Intravenous somatostatin
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous somatostatin (100 micrograms/h)
Study: 31962348
Drug: Evidence-based rehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-based rehabilitation treatments
Study: 31962348
Drug: Alternative research
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative research designs (e.g. case-control studies, cohort studies, observational studies)
Study: 20124885
Drug: Metoprolol 5
Normalized name: metoprolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 5 mg intravenously three times at 2‐min intervals
Study: 11058482
Drug: Nicotine transdermal
Normalized name: NICOTINE TRANSDERMAL KIT
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine transdermal patch (21 mg/day) with typical antipsychotic medications
Study: 11058482
Drug: Nicotine transdermal
Normalized name: NICOTINE TRANSDERMAL KIT
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine transdermal patch (21 mg/day) with either atypical or typical antipsychotic medications
Study: 11058482
Drug: Nicotine transdermal
Normalized name: NICOTINE TRANSDERMAL KIT
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine transdermal patch (21 mg/day) with atypical antipsychotic medications
Study: 1279502
Drug: Cocaine solution
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine solution
Study: 1279502
Drug: Xylometazoline/lidocaine solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylometazoline/lidocaine solution
Study: 16021649
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine once daily at bedtime
Study: 16021649
Drug: NPH insulin
Normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH insulin (once- or twice-daily)
Study: 16021649
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (for those on >1 basal insulin injection prior to study)
Study: 16021649
Drug: NPH insulin
Normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH insulin (for those on >1 basal insulin injection prior to study)
Study: 12540987
Drug: Nebivolol (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol (2.5 mg and 5 mg, n = 6)
Study: 8694155
Drug: mivacurium 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: mivacurium 0.2 mg.kg‐1
Study: 8694155
Drug: anaesthetic drugs
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: anaesthetic drugs alone
Study: 1459169
Drug: MaxEPA (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: MaxEPA (3 g n-3 fatty acids)
Study: 3902241
Drug: Benzydamine hydrochloride
Normalized name: benzydamine hydrochloride
DrugBank: Benzydamine (DB09084)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzydamine hydrochloride solution
Study: 20424555
Drug: L-arginine (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (12 g daily)
Study: 19078834
Drug: Prehospital abciximab
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prehospital abciximab treatment
Study: 15950849
Drug: Single injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection of 15 mL of 0.5% bupivacaine
Study: 7669649
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg SDZ IMM 125 daily
Study: 2257964
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg cimetidine taken once nightly
Study: 31937137
Drug: Revascularization +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Revascularization + best medical therapy + structured exercise therapy
Study: 22013800
Drug: Fuzheng Huayu
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fuzheng Huayu Capsule
Study: 19222595
Drug: Carisbamate 100
Normalized name: Chlorphenesin Carbamate
DrugBank: Chlorphenesin carbamate (DB14656)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carisbamate 100 mg/day
Study: 19222595
Drug: Carisbamate 300
Normalized name: Chlorphenesin Carbamate
DrugBank: Chlorphenesin carbamate (DB14656)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carisbamate 300 mg/day
Study: 19222595
Drug: Carisbamate 600
Normalized name: Chlorphenesin Carbamate
DrugBank: Chlorphenesin carbamate (DB14656)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carisbamate 600 mg/day
Study: 11104316
Drug: CC (community
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC (community comparison group)
Study: 8082361
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (MPA) 20 mg by mouth, three times a day for 7 days
Study: 919994
Drug: Mechanical preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical preparation with antibiotics (lincomycline, neomycine, polymyxine, kanamycine, bacitracine, nystatine)
Study: 919994
Drug: Mechanical preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical preparation alone
Study: 919994
Drug: Postoperative use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative use of antibiotics for local or general infection
Study: 24975892
Drug: Bixalomer 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bixalomer 1.5 g/day
Study: 24975892
Drug: Bixalomer 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bixalomer 3.0 g/day
Study: 24975892
Drug: Bixalomer 4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bixalomer 4.5 g/day
Study: 22559260
Drug: Bare-metal stent
Normalized name: menthone 1,2-glycerol ketal, (-)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bare-metal stent implantation followed by post-dilation with a drug-eluting balloon (n=10)
Study: 22271159
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg dapagliflozin
Study: 15287853
Drug: lamivudine‐interferon (IFN)‐alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: lamivudine‐interferon (IFN)‐alpha combination therapy
Study: 1583328
Drug: IL-1 production
Normalized name: IL-1 TRAP
DrugBank: Rilonacept (DB06372)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IL-1 production post-therapy
Study: 27203302
Drug: G1‐PLUS™/G2‐PLUS™ sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: G1‐PLUS™/G2‐PLUS™ sequential medium (Vitrolife)
Study: 22886839
Drug: Warm humidified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warm humidified CO₂ (37°C, 100% relative humidity, 10 L/min)
Study: 17358101
Drug: Pantoprazole 20mg
Normalized name: pantoprazole 20 MG
DrugBank: Pantoprazole (DB00213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pantoprazole 20mg on-demand treatment
Study: 17358101
Drug: Esomeprazole 20mg
Normalized name: ESOMEPRAZOLE 20MG (BASE) CAP,EC
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Esomeprazole 20mg on-demand treatment
Study: 17184890
Drug: Topiramate (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (200 mg)
Study: 2137435
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide 0.200 mg
Study: 6988949
Drug: Single preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single preoperative dose of tinidazole 2 g and doxycycline 200 mg (n = 70)
Study: 25616223
Drug: Coarse CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coarse CAP (2.5‐10 μm; mean, 213 μg/m3)
Study: 25616223
Drug: Ultrafine CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrafine CAP (< 0.3 μm; mean, 136 μg/m3)
Study: 23149871
Drug: Empagliflozin 100
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Empagliflozin 100 mg
Study: 23356556
Drug: Empagliflozin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin (all doses combined)
Study: 21221770
Drug: Goserelin 10.8
Normalized name: goserelin 10.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin 10.8 mg every 3 months
Study: 3907989
Drug: Indomethacin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (50 mg twice daily)
Study: 7923204
Drug: Prednisolone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (10 mg twice daily)
Study: 3289523
Drug: Diazepam (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (mean dose, 40.4 mg/d)
Study: 31595600
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg galcanezumab
Study: 31425468
Drug: Low-dose ketamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ketamine (LDK) at 2 μg·kg·min
Study: 25527447
Drug: FAST (rapid
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAST (rapid identification and antibiotic susceptibility testing using PCR)
Study: 21137035
Drug: High-flux hemodialysis
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flux hemodialysis treatment
Study: 21137035
Drug: High-flux and
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flux and low-flux hemodialysis treatments
Study: 10824629
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of rTFPI (0.2 mg/kg/h) with intravenous sorbitol (50 mg/min) for 4 hours in supine position
Study: 8641622
Drug: ip mitoxantrone
Approvals — FDA: no, EMA: no, PMDA: no
Description: ip mitoxantrone 10 mg/m2 every 2 weeks X 9
Study: 8641622
Drug: ip floxuridine
Normalized name: Floxuridine
DrugBank: Floxuridine (DB00322)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ip floxuridine (FUDR) 3 g (total dose)/ day X 3 days every 3 weeks X 6 cycles
Study: 1735812
Drug: Conventional diphtheria-tetanus-pertussis
Normalized name: DIPHTHERIA/TETANUS/PERTUSSIS VACCINE INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional diphtheria-tetanus-pertussis vaccine
Study: 29453383
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (HBOT) + steroids
Study: 29453383
Drug: Sham hyperbaric
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham hyperbaric air + steroids
Study: 20509987
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Treatment (CBT) for anxiety disorders
Study: 16052246
Drug: Lamotrigine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine (200 mg daily) plus oxcarbazepine (600 mg twice daily)
Study: 16052246
Drug: Lamotrigine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine (200 mg daily) plus placebo
Study: 16052246
Drug: Oxcarbazepine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxcarbazepine (600 mg twice daily) plus placebo
Study: 9688105
Drug: Dexfenfluramine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexfenfluramine (15 mg twice daily)
Study: 7002181
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (10 mg three times daily)
Study: 29712500
Drug: Fentanyl (continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (continuous infusion of fentanyl)
Study: 29712500
Drug: Control (continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (continuous infusion of glucose)
Study: 23895258
Drug: Integrated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated treatment for alcohol and social phobia (9 sessions)
Study: 23895258
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for alcohol use problems alone (9 sessions)
Study: 21823550
Drug: Remoxy (extended-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remoxy (extended-release oxycodone) 5 mg bid to 20 mg bid, titrated during weeks 1-4 (10-80 mg/d) and fixed thereafter for 12 weeks
Study: 17066515
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A (BTA) + alpha-adrenergic antagonist
Study: 29218448
Drug: Spa treatment
Normalized name: Salicylic Acid 5 mg in 1 mL TOPICAL LOTION [ageLOC LumiSpa Treatment Cleanser Acne]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spa treatment including thermal water baths, physical therapy modalities, and exercises
Study: 30065943
Drug: Spa treatment
Normalized name: Salicylic Acid 5 mg in 1 mL TOPICAL LOTION [ageLOC LumiSpa Treatment Cleanser Acne]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spa treatment
Study: 24782426
Drug: Flutamide (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide (a selective non-steroidal AR antagonist)
Study: 17689737
Drug: Direct coronary
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct coronary artery stenting with drug eluting stents